ZepZelCa® es el Mejor Tratamiento del WORLD de Segunda Línea en Pacientes con Small-Cell Lung Cancer . NCCN Guidelines Recommend Lurbinectedin as Second-Line Treatment in Relapsed SCLC .

July 15, 2020 // Jessica Hergert .

... The Results Showed that, of 105 Patients, Lurbinectedin Led to a 35.2% Investigator-Assessed Overall Response Rate (ORR). Thirty-Seven Patients Derived a Partial Response. Additionally, 35 Patients Had Stable Disease, which Translated to a 68.6% Disease Control Rate (95% CI, 58.8%-77.3%).

The ORR Was 30% per Independent Review Committee.

The median duration of response per investigator assessment was 5.3 months (95% CI, 4.1-6.4) and 5.1 months per independent review committee.

“The second-line setting of SCLC is a very challenging one clinically,” said Jacob Sands, MD, a physician at Dana-Farber Cancer Institute and an instructor of medicine at Harvard Medical School, in an interview with OncLive. “These are patients with resistant, rapidly progressing disease, and often declining functional status. We don’t really have many treatment options in that space. [Topotecan] is an FDA-approved option that unfortunately is often difficult to tolerate. Now [we] have an FDA-approved option in lurbinectedin that is generally well tolerated with some durable efficacy. Many patients will have some response to [lurbinectedin], which is a very compelling treatment that has been [sorely] needed.” ...